 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...155156157158159160161162163164165...235236» |
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 31, 2020
P2, N=101, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Dec 2019
- || Trial completion date, Trial primary completion date: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - Mar 31, 2020
P1/2, N=260, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Dec 2019 Trial completion date: Feb 2022 --> Nov 2021 | Trial primary completion date: Feb 2022 --> Nov 2021
- || TRK-950 / Toray
Enrollment change: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 31, 2020
P1b, N=75, Recruiting, Sponsor: Toray Industries, Inc
Trial completion date: Feb 2022 --> Nov 2021 | Trial primary completion date: Feb 2022 --> Nov 2021 N=36 --> 75
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: FOBEAR: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Mar 31, 2020
P3, N=500, Recruiting, Sponsor: Yanhong Deng
N=36 --> 75 Not yet recruiting --> Recruiting
- ||| TTX-030 / AbbVie, Trishula Therap
Enrollment open, Metastases: ELTIVATE: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers (clinicaltrials.gov) - Mar 30, 2020
P1, N=152, Recruiting, Sponsor: Tizona Therapeutics, Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Trial completion date, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Mar 30, 2020
P2, N=276, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Jul 2020
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion: FFCD 1201 DEBIRI: Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study (clinicaltrials.gov) - Mar 30, 2020
P2, N=58, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Trial completion date: Dec 2019 --> Jul 2020 Active, not recruiting --> Completed
- | Trial completion: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis (clinicaltrials.gov) - Mar 30, 2020
P2, N=65, Completed, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (clinicaltrials.gov) - Mar 30, 2020
P3, N=268, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Active, not recruiting --> Completed Trial primary completion date: Sep 2018 --> Sep 2021
- | Trial completion date, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Mar 30, 2020
P2, N=127, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Sep 2018 --> Sep 2021 Trial completion date: Dec 2019 --> Jul 2020
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial completion date, Metastases: ERMES: Erbitux MEtastatic Colorectal Cancer Strategy Study (clinicaltrials.gov) - Mar 30, 2020
P3, N=606, Completed, Sponsor: Armando Orlandi
Trial completion date: Dec 2019 --> Jul 2020 Recruiting --> Completed | Trial completion date: Aug 2020 --> Mar 2020
- | JNK-IN-8 - Dana-Farber Cancer Institute, University of North Carolina / Chapel Hill
Journal: Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. (Pubmed Central) - Mar 28, 2020
Active JNK1 and JUN are specifically implicated in these effects, and synergy with JNK-IN-8 is linked to FOLFOX-mediated JUN activation, cell cycle dysregulation, and DNA damage response. This study highlights the potential for JNK-IN-8 as a biological tool and potential combination therapy with FOLFOX in PDAC and reinforces the need to tailor treatment to functional characteristics of individual tumors.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer. (Pubmed Central) - Mar 28, 2020
This study highlights the potential for JNK-IN-8 as a biological tool and potential combination therapy with FOLFOX in PDAC and reinforces the need to tailor treatment to functional characteristics of individual tumors. The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Mar 27, 2020
P2, N=17, Active, not recruiting, Sponsor: University of Southern California
The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable. Trial primary completion date: Dec 2019 --> May 2020
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial termination: GCC 1314: Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma (clinicaltrials.gov) - Mar 27, 2020
P2, N=3, Terminated, Sponsor: University of Maryland, Baltimore
Trial primary completion date: Dec 2019 --> May 2020 Completed --> Terminated; Slow accrual, PI left instituion
- ||||| vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial termination, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 27, 2020
P2, N=197, Terminated, Sponsor: Hoffmann-La Roche
Completed --> Terminated; Slow accrual, PI left instituion Completed --> Terminated
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
A case of FOLFIRINOX induced SiADH () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_97;
She had received FOLFOX (leucovorin, fluorouracil, and oxaliplatin) for the first time 7 days earlier and FOLFIRINOX 36 hours earlier...Review of the literature revealed one case report where irinotecan-cisplatin chemotherapy was associated with SIADH on initial administration and with re-administration... Although we cannot prove the FOLFIRINOX was directly related to the occurrence of SIADH in this patient, the timeline of events, existence of prior case report confirming reaction through provocation trial and class relationship to cisplatin strongly suggest a relationship exists.
- leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Incidence of AKI post High-Dose Methotrexate Infusion () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_11;
The incidence of stage 3 AKI or requirement of RRT is < 1% of total doses. Better preventive measures are needed to prevent AKI in these patients.
- | oxaliplatin / Generic mfg., etoposide IV / Generic mfg., irinotecan / Generic mfg.
Biomarker, New P2 trial, Metastases: FOLFIRINEC: Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (clinicaltrials.gov) - Mar 26, 2020
P2, N=218, Not yet recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | New P1/2 trial, Metastases: ChanghaiH-PP05: Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 26, 2020
P1/2, N=60, Recruiting, Sponsor: Changhai Hospital
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal, HEOR: Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. (Pubmed Central) - Mar 26, 2020
Better preventive measures are needed to prevent AKI in these patients. UFT/LV was the more cost-effective treatment as adjuvant chemotherapy.
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., Zaltrap (ziv-aflibercept IV) / Sanofi
Clinical, P2 data, Journal: FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. (Pubmed Central) - Mar 26, 2020
Ziv-aflibercept did not increase the anti-tumor activity of first-line mFOLFOX6 in metastatic esophagogastric cancer, potentially because of decreased dose intensity of FOLFOX. Further evaluation of ziv-aflibercept in unselected, chemotherapy-naive patients with metastatic esophagogastric adenocarcinoma is not warranted.
- | leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Preclinical, Journal: Electropermeabilization of metastatic chondrosarcoma cells from primary cell culture. (Pubmed Central) - Mar 25, 2020
Although combining cisplatin and leucovorin together increased their toxicity and supported apoptosis, application of pulsed electric fields brought no advantage for their efficacy. The study emphasizes the need for introduction of primary cell cultures into studies on pulse electric fields as model frequently less sensitive to PEF-based treatments than continuous cell lines.
- || fluorouracil topical / Generic mfg., OvaRex (oregovomab) / Quest PharmaTech
Clinical, P1/2 data, Journal: Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. (Pubmed Central) - Mar 25, 2020
P2
A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity. Re-evaluation with modern systemic paradigms is recommended.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report (Pubmed Central) - Mar 25, 2020
After nCRT with consolidation chemotherapy or TNT for low rectal cancer, patients with cCR, ycN0 according to PET-CT and MRI, and ypT0 after local excision, can consider the W&W strategy. Strict patient selection with a near-cCR for local resection and sphincter-preserving strategy can reduce the local regrowth of cancer, and the short-term outcomes are satisfactory.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. (Pubmed Central) - Mar 25, 2020
FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX. The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.
- | Erbitux (cetuximab) / Eli Lilly
Phase classification, Enrollment change, Trial termination, Metastases: SKINUX: Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer (clinicaltrials.gov) - Mar 25, 2020
P=N/A, N=25, Terminated, Sponsor: Institut Cancerologie de l'Ouest
The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors. Phase classification: P3 --> P=N/A | N=130 --> 25 | Recruiting --> Terminated; The study stopped due to a lack of recruitment
- | Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Trial primary completion date, Metastases: TIME-PRODIGE 28: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - Mar 25, 2020
P2, N=139, Active, not recruiting, Sponsor: UNICANCER
Phase classification: P3 --> P=N/A | N=130 --> 25 | Recruiting --> Terminated; The study stopped due to a lack of recruitment Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Aug 2020
- | Biomarker, Trial completion date, Trial primary completion date, Metastases: PAMELA70: Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 24, 2020
P2, N=72, Active, not recruiting, Sponsor: Institut Cancerologie de l'Ouest
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2019 --> Aug 2020 Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2019 --> Jul 2020
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Enrollment closed: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 24, 2020
P3, N=218, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2019 --> Jul 2020 Completed --> Active, not recruiting
- | thioguanine / Generic mfg.
Enrollment closed: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 24, 2020
P3, N=5377, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting Completed --> Active, not recruiting
- || Lumakras (sotorasib) / Amgen
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Mar 24, 2020
P1b, N=250, Recruiting, Sponsor: Amgen
Completed --> Active, not recruiting N=120 --> 250 | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Sep 2022 --> Apr 2022
- | Trial primary completion date: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Mar 23, 2020
P1/2, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
N=120 --> 250 | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Sep 2022 --> Apr 2022 Trial primary completion date: Feb 2020 --> Jul 2021
- || Clinical, Observational data, Journal, Combination therapy, Real-World Evidence: Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. (Pubmed Central) - Mar 20, 2020
Overall, the study results show that treatment patterns, clinical efficacy, and the safety profile of panitumumab in routine clinical practice were comparable to those in randomized controlled trials. The relatively low skin toxicity rate could be attributed to increasing experience in managing panitumumab-associated rash and some degree of underreporting.
- | Trial completion date, Trial primary completion date: A Study in Adults With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 20, 2020
P2, N=100, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
The relatively low skin toxicity rate could be attributed to increasing experience in managing panitumumab-associated rash and some degree of underreporting. Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Jul 2019 --> Jul 2021
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: mFLOT Chemotherapy as First-line Treatment in GC (clinicaltrials.gov) - Mar 20, 2020
P1/2, N=18, Completed, Sponsor: Ruijin Hospital
Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Jul 2019 --> Jul 2021 Recruiting --> Completed | N=56 --> 18 | Trial completion date: Jul 2024 --> Jan 2020 | Trial primary completion date: Jul 2021 --> Nov 2019
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Phase classification: GIANT: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (clinicaltrials.gov) - Mar 19, 2020
P2, N=184, Not yet recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Recruiting --> Completed | N=56 --> 18 | Trial completion date: Jul 2024 --> Jan 2020 | Trial primary completion date: Jul 2021 --> Nov 2019 Phase classification: P3 --> P2
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers. (Pubmed Central) - Mar 19, 2020
Patients with well- and moderately-differentiated histological grade of the tumor showed a better response rate (100.00% of 2 patients and 66.66% of 12 patients, respectively) compared to those with poorly differentiated (0.00% of 26 patients) histological grade (p < 0.001). Further multicenter studies are recommended to confirm conclusively our findings.
- | Enrollment open, Metastases: EA2183: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (clinicaltrials.gov) - Mar 18, 2020
P3, N=314, Recruiting, Sponsor: ECOG-ACRIN Cancer Research Group
Further multicenter studies are recommended to confirm conclusively our findings. Not yet recruiting --> Recruiting
- || leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia. (Pubmed Central) - Mar 18, 2020
Intracellular folate levels accumulate after HD-MTX and Leucovorin therapy in children with ALL, suggesting that Leucovorin restores the intracellular folate pool. Future studies are necessary to assess concomitant lower uptake of MTX.
- | abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
Enrollment change, Trial withdrawal, Combination therapy, Metastases: AMELION: Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Mar 18, 2020
P2, N=0, Withdrawn, Sponsor: SFJ Pharmaceuticals X, LTD.
Future studies are necessary to assess concomitant lower uptake of MTX. N=230 --> 0 | Not yet recruiting --> Withdrawn
- | pegilodecakin (LY3500518) / Eli Lilly
Trial completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 17, 2020
P1, N=350, Active, not recruiting, Sponsor: Eli Lilly and Company
N=230 --> 0 | Not yet recruiting --> Withdrawn Trial completion date: Feb 2020 --> Nov 2020
- || gene-modified anti-CEA T cells / Sorrento
Trial initiation date, CAR T-Cell Therapy: Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases (clinicaltrials.gov) - Mar 17, 2020
P2b, N=167, Not yet recruiting, Sponsor: Sorrento Therapeutics, Inc.
Trial completion date: Feb 2020 --> Nov 2020 Initiation date: Nov 2019 --> Nov 2021
- | Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: REVOLUTION: Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 16, 2020
P2, N=200, Recruiting, Sponsor: National Cancer Institute, Naples
- || Clinical, Journal: Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. (Pubmed Central) - Mar 16, 2020
P3
Of 766 treated patients enrolled, 59.5% were male, 94.8% had an Eastern Cooperative Oncology Group performance status of 0-1, all received previous chemotherapy (97.8% including oxaliplatin), and 58.6% had prior exposure to bevacizumab...Aflibercept in combination with FOLFIRI is a safe and efficacious regimen administered in current clinical practice to patients with mCRC previously treated with oxaliplatin. The study results, conducted in real-world clinical practice with a less selected patient population, are aligned with the VELOUR (NCT00561470) trial and no new safety issues were identified.
- || dilpacimab (ABT-165) / AbbVie
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Mar 16, 2020
P1, N=100, Active, not recruiting, Sponsor: AbbVie
The study results, conducted in real-world clinical practice with a less selected patient population, are aligned with the VELOUR (NCT00561470) trial and no new safety issues were identified. Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
A Case of Fulminant Type 1 Diabetes Mellitus and Diabetic Ketoacidosis Caused by Adjuvant Chemotherapy for Colon Cancer (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area E) - Mar 15, 2020 - Abstract #ATS2020ATS_8149;
We report a rare complication of FOLFOX in which a patient developed severe DKA due to FT1D. Further studies are needed to investigate the underlying mechanism.
- A Rare Case of Primary Cardiac Burkitt Lymphoma (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) - Mar 15, 2020 - Abstract #ATS2020ATS_6736;
Treatment consists of a mixture of surgery, chemotherapy, radiation, and stem cell transplantation. Expedient debulking and initiation of chemotherapy is imperative, as Burkitt lymphoma is rapidly progressive and obstructing intracardiac masses can cause hemodynamic compromise.
- leucovorin calcium / Generic mfg.
A Case of CNS Iris in a Patient with AIDS (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) - Mar 15, 2020 - Abstract #ATS2020ATS_6528;
Toxoplasma-associated CNS IRIS can show worsening of MRI scans even as T. gondii parasite loads decrease. The treatment is focused on reducing cerebral edema, and treatment of the underlying infection.
- || Clinical, Journal: Organizing pneumonia secondary to cetuximab in a patient with colorectal cancer. (Pubmed Central) - Mar 15, 2020
Although pulmonary toxicity secondary to cetuximab is uncommon, it is important to recognize, as it may be associated with poor prognosis. To the best of our knowledge, this is the first report of OP attributed to cetuximab with histopathological evidence.